Therapeutic Strategy for Diabrtes mellitus by Hepatic Stem cell

有效的免疫抑制剂的开发已经显著提高了器官移植中移植物和患者的存活率，并且在过去几年中促进了医学移植的进步。诱导供体特异性耐受（DST）被广泛认为是解决这些问题的最有效的方法。嵌合体被认为是诱导DST的一种有吸引力的方法，并且已经发表了许多关于这种现象的研究。混合嵌合体可以通过将来自组织不相容供体小鼠的骨髓（BM）与与受体小鼠组织相容的BM一起移植到致死辐射的受体小鼠中来产生，使得受体造血细胞可以部分地被供体相容细胞替代。与异源嵌合体相比，混合嵌合体更稳定，对与BM移植物排斥相关的致死性BM发育不全更不敏感。鉴于脾细胞在临床实践中的可用性，我们一直专注于使用脾细胞作为建立耐受性的细胞来源。脾细胞是一种有吸引力的细胞来源，与之形成嵌合体，因为它们是淋巴细胞的丰富来源。在目前的研究中，我们证实了这一假设，即含有丰富的免疫细胞的脾细胞是有效的维持嵌合体和改善长期移植物存活的小鼠。

The development of effective immunosuppressants has dramatically improved both graft and patient survival rates in organ transplantation, and has contributed to advances in medical transplantation during the past few years. Inducing donor-specific tolerance (DST) is widely believed to be the most effective solution to these problems. Chimerism is viewed as an attractive approach to inducing DST, and many studies of this phenomenon have been published. A mixed chimera can be created by transplanting bone marrow (BM) from histoincompatible donor mice to lethally-irradiated recipient mice, together with BM that is histocompatible with the recipient mice, so that the recipient haematopoietic cells can be partially replaced by donor-compatible cells. Compared to an allochimera, a mixed chimera is more stable and less susceptible to the lethal BM aplasia associated with BM graft rejection. We have focused on using splenocytes as a source of cells for establishing tolerance, in view of their availability for use in clinical practice. Splenocytes are an attractive source of cells with which to develop chimerism because they are a rich source of lymphocytes. In the current study, we verified the hypothesis that splenocytes containing abundant immunocytes are effective for maintaining chimerism and improving long-term graft survival in mice.